Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial

Leqvio (inclisiran) - Novartis

SYH2053 - CSPC Pharma

ezetimibe - Generic mfg.

FF Wang1; SY Zeng2; S Zhang3; XY Ji3; J Zhang4; YM Zhong5; HZ Chen6; JM Zhang7; HT Lu8; K Ding9; T Quan10; LL Yao11; P Xue12; YD Tang1

May 11, 2026